Approval · Notice of Compliance 29434 · 2022
KADCYLA: Notice of Compliance 29434
Issued November 9, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 29434
- Date
- November 9, 2022
- Company
- Hoffmann-La Roche LimitedMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Additional drug substance manufacturing site
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| KADCYLA | Not yet assigned | — |
Medicinal ingredients
- TRASTUZUMAB EMTANSINE 100 MG per VIAL
- TRASTUZUMAB EMTANSINE 160 MG per VIAL